Key clinical point: Hidradenitis suppurativa (HS)-associated Crohn's disease (CD) is more active, requires greater use of anti-tumor necrosis factor (anti-TNF) agents and is associated with an increased risk of permanent stoma.

Major finding: CD with HS was more active than CD without HS (56% vs. 40% years with active disease) and was associated with greater use of anti-TNF agents (39% vs. 23% years spent with anti-TNF agents; P less than .001 for both). HS was independently associated with a higher risk for permanent stoma in patients with CD (odds ratio, 6.19; P less than .001).

Study details: The data come from a retrospective study of 4,645 patients with CD (CD with HS, n=44; CD without HS, n=176).

Disclosures: No study sponsor was identified. The authors declared no conflicts of interest.